Retinopathy News and Research

RSS

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people – including children – in the United States. Approximately one-quarter of those people do not know they're living with the disease.

23 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

CVVS scientist receives top UK award for ground-breaking research on vascular stem cells, eye disease

One of Northern Ireland's leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen's University.

5 Feb 2011

Queen’s scientist awarded Royal Society Wolfson Research Merit Award

One of Northern Ireland's leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen's University.

4 Feb 2011

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

DMP1 protein prevents endothelial cells to respond to VEGF

A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.

27 Jan 2011

What protects certain diabetics from complications?

Much research has been carried out on why diabetics develop complications. Now researchers are asking the question the other way around. They want to know why some diabetic patients do not develop complications. What is it that protects them? The PROLONG study could provide the answer.

21 Jan 2011

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

14 Jan 2011

Ifa Systems acquires inoveon

ifa Systems AG, the global leader for IT solutions in ophthalmology based in Cologne, Germany, announced the acquisition of inoveon Corporation, proven experts in detection, staging, and monitoring of diabetic retinopathy and macular edema.

10 Jan 2011

Type 2 diabetics who consume alcohol at increased risk for blurry vision

A new study published in the journal Diabetic Medicine reveals that among patients with type 2 diabetes, alcohol consumption was associated with an increased risk of deterioration of visual acuity.

2 Dec 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Krieger Eye Institute at Sinai Hospital opens new center for treatment of retinal diseases

The Krieger Eye Institute at Sinai Hospital opened a new center for the treatment of retinal diseases in November. The retina is the layer of tissue at the back of the eye that converts images to electrical impulses. These electrical signals are then perceived by the brain as sight.

18 Nov 2010

Study reveals true effects of malaria on African generations

Almost a third of cerebral malaria survivors developed epilepsy or other behavioral disorders in the most comprehensive study to date of the disease in African children, solidifying the link between malaria and neuropsychiatric disorders that affect hundreds of thousands of children.

17 Nov 2010

ATA publishes 'A blueprint for telerehabilitation guidelines'

The American Telemedicine Association (ATA) has just announced its latest standard publication, 'A Blueprint for Telerehabilitation Guidelines,' which discusses the key administrative, clinical technical and ethical principles that should be considered in the course of providing telerehabilitation services. The purpose of these guidelines is to inform and assist practitioners in providing effective and safe services based on client needs, current empirical evidence, and available technologies.

15 Nov 2010

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.

10 Nov 2010